Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 266

Similar articles for PubMed (Select 23154554)

1.

Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.

Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta ND, Lipton L, García-Sáenz JA, Pereira JR, Prabhash K, Ciuleanu TE, Kanarev V, Wang H, Balakumaran A, Jacobs I.

J Thorac Oncol. 2012 Dec;7(12):1823-9. doi: 10.1097/JTO.0b013e31826aec2b.

PMID:
23154554
2.

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.

3.

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.

Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H.

Support Care Cancer. 2014 Mar;22(3):679-87. doi: 10.1007/s00520-013-2022-1. Epub 2013 Oct 26.

PMID:
24162260
4.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.

J Med Econ. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380. Epub 2012 Mar 27.

PMID:
22409231
5.

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.

J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.

6.

Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis.

Sun L, Yu S.

Am J Clin Oncol. 2013 Aug;36(4):399-403. doi: 10.1097/COC.0b013e31824be20e. Review.

PMID:
22772430
7.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.

Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.

PMID:
22975218
8.

Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.

Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K.

Cancer. 2013 Feb 15;119(4):832-8. doi: 10.1002/cncr.27789. Epub 2012 Sep 5.

9.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C.

Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.

10.

Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.

Wang Y, Tao H, Yu X, Wang Z, Wang M.

Clin Lung Cancer. 2013 May;14(3):254-60. doi: 10.1016/j.cllc.2012.09.001. Epub 2012 Oct 25.

PMID:
23103352
11.

Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K.

Support Care Cancer. 2013 Dec;21(12):3497-507. doi: 10.1007/s00520-013-1932-2. Epub 2013 Aug 22.

PMID:
23975226
12.

Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.

Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, Henry DH, Novello S, Hungria V, Qian Y, Feng A, Yeh H, Chung K.

Ann Oncol. 2012 Dec;23(12):3045-51. doi: 10.1093/annonc/mds175. Epub 2012 Jul 31.

13.

Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.

Inanc M, Kaynar L, Enhos S, Pala C, Karaca H, Berk V, Ozkan M, Sıvgın S, Eser B, Cetin M, Elmali F.

Med Oncol. 2014 Mar;31(3):837. doi: 10.1007/s12032-013-0837-8. Epub 2014 Jan 22.

PMID:
24448976
14.

Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.

Calderone R, Nimako K, Leary A, Popat S, O'Brien ME.

Eur J Cancer. 2011 Jul;47(11):1603-5. doi: 10.1016/j.ejca.2011.05.008. Epub 2011 Jun 16.

PMID:
21684152
15.

Bisphosphonates and other bone agents for breast cancer.

Wong MH, Stockler MR, Pavlakis N.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD003474. doi: 10.1002/14651858.CD003474.pub3. Review.

PMID:
22336790
16.

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.

Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE.

J Thorac Oncol. 2008 Mar;3(3):228-36. doi: 10.1097/JTO.0b013e3181651c0e.

PMID:
18317064
17.

Why denosumab obtains a survival benefit over zoledronic acid in bone metastatic lung cancer patients?

Deiana L, Claps M, Berruti A.

J Thorac Oncol. 2013 Aug;8(8):e79. doi: 10.1097/JTO.0b013e318293e443. No abstract available.

PMID:
23857407
18.

Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.

Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F.

J Oral Maxillofac Surg. 2013 Sep;71(9):1532-40. doi: 10.1016/j.joms.2013.03.019. Epub 2013 May 1.

PMID:
23642545
19.

Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.

Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman RE, Paterson AH, Gao GM, Kinsey AC, Peterson MC, Jun S.

Clin Cancer Res. 2008 Oct 15;14(20):6690-6. doi: 10.1158/1078-0432.CCR-07-5234.

20.

Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.

Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A.

Clin Cancer Res. 2012 Sep 1;18(17):4841-9. Epub 2012 Aug 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk